On February 25, 2022, Richard C. Williams notified Adamis Pharmaceuticals Corporation that effective April 15, 2022, he will be retiring, after serving the company since August 2014. He will be resigning from his position as a director, Chairman of the Board of Directors and a member of the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board. Mr. Williams indicated to the company that he is retiring only for personal reasons unrelated to any company operations, policies, practices, or financial statements.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 USD | -8.33% | 0.00% | -95.72% |
May. 30 | First Motion for Exclusivity Period Extension Filed by DMK Pharmaceuticals Corporation | CI |
May. 08 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
1st Jan change | Capi. | |
---|---|---|
-95.72% | 303K | |
+47.22% | 765B | |
-5.98% | 354B | |
+20.22% | 331B | |
+9.25% | 299B | |
+19.09% | 248B | |
-1.76% | 219B | |
+11.04% | 216B | |
+5.18% | 164B | |
-2.62% | 162B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- Richard C. Williams Notifies Adamis Pharmaceuticals Corporation That Effective April 15, 2022, He Will Be Retiring